Abstract Osteoblastic metastases and osteosarcoma can avidly concentrate bone-seeking radiopharmaceuticals. We sought to increase effectiveness of high-dose 153 Samarium ethylenediaminetetramethylenephosphonate ( 153 Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine. Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153 Sm-EDTMP. Gemcitabine was administered 1day after samarium infusion. Residual total body radioactivity was within the safe range of <3.6 mCi on day +14 (1.1 F 0.4 mCi; range, 0.67-1.8 mCi).
Although bone metastases of primary bone tumors herald a very poor prognosis (1, 2) , radiotherapy can be help control disease and reduce pain (3, 4) . There has been little improvement in results of osteosarcoma chemotherapy protocols in the past decade; most programs achieve 55% to 70% survival in nonmetastatic extremity tumors (5 -7). There is a need for improved control for patients with osteosarcoma in axial sites (40-60% control; refs. 8 -10) , metastases (20-30% durable control; ref. 2) , or recurrent disease (10-20% control; ref. 11) . With modern therapy, about 20% of relapses occur in bone (12) . 153 Samarium ethylenediaminetetramethylenephosphonate ( 153 Sm-EDTMP) is a bone-seeking radiopharmaceutical (Table 1) designed to selectively deliver radiation to osteoblastic skeletal metastases (13 -18) . Use of 153 Sm-EDTMP has been described in canine (19, 20) and human osteosarcoma (21 -24) . Although the dose-limiting toxicity of 153 Sm-EDTMP is pancytopenia related to radiation of bone marrow, the relatively short half-life of this h-emitting radioisotope (47 hours) has permitted a 30-fold dose increase if stem cell support is provided 2 weeks after administration (22, 23) .
One means to improve the therapeutic index of radiotherapy against sarcomas is the use of a radiosensitizer (25) . Gemcitabine is a nucleoside analogue with activity against solid tumors (26 -28) and is a radiation sensitizer (29 -34) . Because 153 Sm-EDTMP has very little washout after skeletal localization (35, 36) , gemcitabine after 153 Sm-EDTMP should facilitate improved radiobiological effectiveness against cancer cells in the immediate vicinity of the radioisotope. In this report, we sought to determine toxicity and effects of targeted skeletal radiation using gemcitabine after 153 Sm-EDTMP in patients with osteosarcoma.
Materials and Methods
Patients with metastatic, unresectable, progressive, and/or recurrent osteosarcoma involving bone were eligible for treatment and accrued during 2001 to 2003 if:
1. state-of-the art chemotherapy (e.g., two or more regimens) had been given, 2. at least one osteoblastic indicator lesion was observable on 99m Tc-MDP bone scan (qualitative, yes/no increase in osteoblastic activity compared with contralateral side) 3. other therapies of higher priority for local control (e.g., surgery or radiotherapy) were either not possible or refused 4. age was z12 years and adolescents had achieved growth potential or were willing to accept linear growth delay from radiation to growth plates.
Autologous hematopoietic stem cells were cryopreserved. Informed consent was obtained in all patients after consultation including discussion of indications, risks, and alternatives. Patient characteristics and indicator lesion(s) are in Table 2 . Stem cells were harvested using a variety of chemotherapy regimens followed by granulocyte colonystimulating factor. All patients had central lines for 153 Sm-EDTMP infusion, hydration, stem cell infusion, blood count monitoring, and transfusions. Sm-EDTMP (Quadramet, Cytogen, Princeton, NJ) infusions were scheduled on Wednesdays; thus, the high-dose infusion would have the highest specific activity. To decrease risk of symptomatic hypocalcemia, 1,000-mg calcium carbonate was given orally every hour for 3 hours before the 153 Sm-EDTMP infusion. Calcium gluconate (10%; 7.5 mg/kg in 50 mL D5W) was available for treatment of hypocalcemia but was not needed in any patient.
Samarium administration. Hydration consisted of D5 and 0.45% NaCl with KCl 20 meq/L at 125 mL/m 2 /h for 3 hours. 153 Sm-EDTMP was thawed and placed into a 60-mL lead-shielded plastic syringe.
153 Sm-EDTMP (30 mCi/kg; 1,110 MBq/kg) was infused i.v. via a central line using small bore pediatric tubing to minimize the amount remaining in the tubing that was flushed into the patient at the end of the infusion using 10 mL of 0.9% NaCl. Furosemide (0.5 mg/kg i.v.) was then given. Instructions to empty the bladder frequently (e.g., q 1-2 hours Â 6 hours) were given and i.v. hydration was continued for about 20 hours after the samarium infusion.
Gemcitabine administration. Antiemetic therapy consisted of granisetron (1 mg orally) and dexamethasone (8 mg orally). Gemcitabine (Gemzar; Lilly, Indianapolis, IN; 250 mg/m 2 /dose in the first two patients using daily Â 2, rest day, then daily Â 2 patient 1; daily Â 5 patient 2 and 1,500 mg/m 2 in the subsequent 12 patients) was diluted in 500 mL of 0.9% NaCl and administered i.v. over 30 minutes. Chemotherapy was done as an outpatient. Gemcitabine schedule was initially repetitive daily dosing with daily Â 2, day of rest, then daily Â 2 (patient 1; patient choice not to get dose 3 of 5), then daily Â 5 (patient 2). When this patient developed unexpected grade 4 mucositis, the schedule the single dose schedule 18 to 24 hours after was used (patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Whole body radioactivity was measured at three time points (usually day +1, +2, and +5; e.g., Thursday, Friday, and Monday after samarium). Residual radioactivity was estimated for day 14 after 153 Sm-EDTMP to confirm that total body radiation was <3.6 mCi, the safe upper limit for stem cell infusion. Autologous stem cells were thawed and infused 2 weeks s/p 153 Sm-EDTMP according to standard clinical guidelines. Patients received routine supportive care including red cell and platelet transfusions. Levofloxicin (500 mg) orally daily and either granulocyte colony-stimulating factor or granulocyte macrophage colony-stimulating factor was given s.c. daily after stem cells until neutrophil recovery.
Imaging and follow-up studies. Bone scans and in selected cases, chest computerized tomography and positron emission tomography scans were done. Serum alkaline phosphatase and creatinine were monitored. Imaging responses were defined as complete remission: the disappearance of lesion(s) on bone scan or positron emission tomography scan; partial remission: persistence but improvement on bone and/or positron emission tomography; stable: no change; and progression: appearance of new lesions or >25% increase in size of an indicator lesion measured using computerized tomography scan. Because patients were accrued 2001 to 2003, follow-up was available on all patients for at least 1 to 2 years.
Results
High-dose samarium and radioactive decay. A total of 14 patients received high-dose 153 Sm-EDTMP and gemcitabine as described in Tables 2 and 3 . Using 30 mCi/kg actual weight calculation, an average of 1,640 mCi 153 Sm-EDTMP was administered. The residual radioactivity before stem cell infusion (i.e., 14 days after high-dose 153 Sm-EDTMP) was about 1 mCi (range, 0.67-1.8; Table 4 ). This amount was within the safe limit of <3.6 mCi for stem cell infusion.
Performance. The treatment group had variable performance status before treatment (Table 2 ). After treatment, all patients maintained stable or improved performance status except the single patient with poor initial performance status of 2. This patient had some alleviation of pain but did not improve enough to have outpatient pain management.
Toxicity. Neither nephrotoxicity nor hemorrhagic cystitis was a problem. Serum creatinine did not change nor was hematuria seen. As expected, all patients had temporary cytopenias. All patients required transfusions and were supported with granulocyte colony-stimulating factor or granulocyte macrophage colony-stimulating factor. The most serious toxicity was life-threatening pulmonary hemorrhage in a patient with multiple (>50), small lung metastases in addition to indicator bone lesion in the tibia. This occurred during severe thrombocytopenia (platelets < 10,000). Hemorrhage resolved with supportive care including transfusions and administration of one dose (5.8 mg) of factor VIIa i.v. Mucositis was related to gemcitabine schedule and occurred only in the patient that was given low dose gemcitabine daily Â 5. This patient also had poor oral intake from headache related to brain edema associated with a skull metastasis adjacent to the frontal lobe. No mucositis was seen after a much larger single dose of gemcitabine 1 day after samarium infusion. Five of 14 patients had fever when neutropenic. No patient with performance status of 0 had fever, but 50% (four of eight) patients with performance status of 1 had fever. Although temporary lymphopenia was observed, there were no fungal or unusual opportunistic infections.
Stem cell grafts. In this very heavily pretreated cohort, 11 of 14 patients had successful peripheral blood stem cell harvesting and infusion (Table 3 ). In one of the three patients that had bone marrow harvested, delayed engraftment occurred. This patient also had the lowest number of nucleated marrow cells (1 Â 10 8 /kg) infused. Recovery of leukocytes occurred within 3 weeks of peripheral blood progenitor cell infusion in all patients. Platelet recovery was more variable and as expected was longer in those that had marrow grafts.
Response and quality of life. Alkaline phosphatase decreased in six of eight patients in which both pre-therapy and posttherapy values were available (Table 5 ). Flair reaction requiring opiates for pain was uncommon (1 of 14) . Indicator lesions were improved on imaging in 8 of 14. In the 12 patients with follow-up of >1 year, the longest duration of response was 11 months. Pattern of failure was progression at site of previous disease in 11 of 14 and development of new or worse pulmonary metastases in 3 of 14. Figure 1 shows representative imaging of osteoblastic tumors treated with 153 Sm-EDTMP + gemcitabine. Early and rapid improvement in bone scan uptake were seen in some patients.
Discussion
Osteosarcoma is characterized by osteoid formation within the tumor. Effective therapy should involve local control with physical means (e.g., surgery and/or radiotherapy) as well as systemic therapy. Chemotherapy protocols have produced survival rates in the 55% to 70% range for nonmetastatic extremity osteosarcoma (37) . Ifosfamide and etoposide have proven activity in metastatic osteosarcoma (1, 38) . Efforts to increase the dose intensity of preoperative or high-risk disease have not improved results (11, 39, 40) . This may be a function of innate insensitivity to chemotherapy (41) .
Some newer chemotherapy agents have cytotoxic activity that is ''non-cross-resistant.'' Aerosol gemcitabine has promising activity in murine osteosarcoma (42) . Monoclonal antibodies with specificity against osteosarcoma are another option but have problems associated with heterogeneous targeting and nonspecific binding (43 -45) . The biology of osteosarcoma and potential targets of therapy has been recently reviewed (46) .
Radiotherapy is considered only modestly effective in osteosarcoma and is generally used in situations when surgery is not possible or for pain (4) . Radiotherapy had better than expected local control of extremity osteosarcoma in those that were also responding to chemotherapy (3). Previous experience using 153 Sm-EDTMP for osteoblastic osteosarcoma has indicated that this bone-seeking radiopharmaceutical could be given at a very high dose to achieve significant radiation doses within tumors with minimal toxicity (23) .
Radiosensitization with gemcitabine has been shown to occur in vitro and in vivo (32 -34, 47, 48) . Because 153 Sm has a half-life of 47 hours, our initial attempt was to use a low daily dose (250 mg/m 2 ) of gemcitabine. Like an earlier report (49), a 5-day schedule of gemcitabine was toxic and associated with significant mucositis (>1 week); thus, the daily gemcitabine schedule was abandoned. However, a single 1,500 mg/m 2 gemcitabine dose after samarium had no immediate significant side effects. (35) . Previous dosimetry measurements have shown organ/ bone ratios with f700-fold more 153 Sm radioisotope deposited in bone compared with liver. This is in contrast to monoclonal antibodies in which organ/bone or bone marrow ratios are f1 to 2. Thus, 153 Sm-EDTMP is the most specific agent commercially available for targeting osteoblastic metastases of osteosarcoma. 223 Radium is a newer bone-seeking radioisotope that has a emission and is being developed in Norway (50) . Because 223 Ra is relatively marrow sparing compared with 153 Sm-EDTMP, this bone-seeking radioisotope may also have usefulness or synergy with 153 Sm-EDTMP against osteosarcoma.
Our patient population consisted of relapsed, resistant, and/or refractory patients with osteosarcoma bone lesions in palliative situations. Nevertheless, 8 of 14 had objective responses. To have more durable clinical responses, it probably will be necessary to follow similar principles as primary therapy of osteosarcoma whenever possible. These principles include (a) use of physical means for additional local control and (b) systemic control with chemotherapy. Principles learned from our study of 153 Sm-EDTMP and gemcitabine for treatment of osteosarcoma may provide a useful new paradigm for treatment of other cancers with osteoblastic bone metastases. Sm-EDTMP + gemcitabine therapy. Positron emission tomography (PET) scan showed improvement of numerous lesions 6 weeks after treatment.
